Phase 3 trials have demonstrated that INH is as efficacious as subcutaneously (SC) injected regular human insulin in type 1 diabetes (T1DM) [14,15] or T2DM [16], and superior to OAs in T2DM [17-20]. This evidence concerns the gene INS and type 1 diabetes mellitus.